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Severely obese patients undergoing bariatric surgery (BS) are at increased risk for venous thromboem-
bolism(VTE).Howstandard lowmolecularweightheparin (LMWH)regimenshouldbeadapted toprovide
bothsufﬁcientefﬁcacyandsafety in this setting isunclear.Weaimed tocompare the inﬂuenceof fourbody
size descriptors (BSD) on peak anti-Xa levels in BS obese patients receiving LMWH ﬁxed doses to identify
which one had the greatest impact. One hundred and thirteen BS obese patients [median body mass
index (BMI), 43.3 kg/m2 (IQR, 40.6–48.7 kg/m2)] receiving subcutaneous dalteparin 5000 IU twice daily
were included in this prospective monocenter study. Peak steady-state anti-Xa levels were measured
peri-operatively following thromboprophylaxis initiation. Only 48% of patients achieved target anti-Xa
levels (0.2–0.5 IU/ml). In univariate analysis, age, gender, total body-weight (TBW), lean body-weight
(LBW), ideal body-weight (IBW), BMI and estimated glomerural ﬁltration rate (eGFR) were associated
with anti-Xa levels. The strongest negative association was observed with LBW (r =−0.56, p < .0001).
Receiver operating characteristic curves indicated that amongBSD, LBW(cut-off >55.8 kg) had thehighest
∗ Corresponding author at: Aix Marseille Univ, INSERM, UMR1263, INRA, C2VN, 
arseille, France.
-mail address: benedicte.gaborit@ap-hm.fr (B. Gaborit).sensitivity (73%) and speciﬁcity (69%) to predict sub-prophylactic anti-Xa levels. In multivariate analysis,
LBW and eGFR remained associated with anti-Xa levels (=−0.47±0.08, p < .0001 and =−0.19±0.08;
p= .02, respectively). In BS morbidly obese patients receiving LMWH for thromboprophylaxis after BS,
LBWand eGFR are themain determinants of anti-Xa level, and could be proposed in LMWH-based throm-
boprophylaxis dosing algorithms. The efﬁcacy of a LBW-scale based dosing algorithm for optimal VTE
er prprevention deserves furth
. IntroductionSevere obese patients undergoing bariatric surgery (BS) are at
ncreased risk for venous thromboembolism (VTE) [1–3] and VTE-ospective randomized trials.
relatedmortality [4–6]. Efﬁcient thromboprophylaxis is thushighly
warranted.
Given their pharmacokinetic proﬁle, their better bioavailability,
and theirmorepredictable anticoagulant effect, standardﬁxeddos-
ing of low molecular weight heparins (LMWH), without the need
for monitoring or adjusting regimens, have become the therapy of
choice for VTE prophylaxis in both medical and surgical setting.
However, in severe obese patients, changes in body composition,
renal glomerular ﬁltration, volume of distribution, cardiac output
a
r
p
b
h
t
l
a
l
d
a
s
i
s
l
t
o
t
I
c
h
b
o
u
s
L
a
a
e
s
b
p
a
r
p
2
2
f
U
a
l
2
n
d
s
a
E
4
n
A
i
n
p
s
D
c
tnd metabolic processes may considerably affect drug response,
esulting in either under or overdosing [7].
Scarce pharmacodynamic studies using LMWH for VTE pro-
hylaxis in severely obese patients found a negative correlation
etween plasma anti-Xa activity and body weight, suggesting that
igher than standard LMWH ﬁxed dosing would be required in
hesepatients [8–10].Moreover, several observational studies chal-
enged the notion that LMWH standard ﬁxed dosing results in
dequate prophylaxis in this speciﬁc population. Indeed, prophy-
actic anti-Xa levels were not achieved with standard ﬁxed LMWH
osing in most cases [11–15], whereas the proportion of patients
chieving appropriate anti-Xa levels increased with higher than
tandard ﬁxed dosing [11–14]. However, increasing the dosing
n parallel with body weight without gate seems hazardous in
everely obesepatients.Consequently, current international guide-
ines do not mention whether LMWH dose should be adjusted, and
o what extent [16–19].
In the lack of consensus regarding how adjusting LMWH dose in
bese patients, differentweight-scales have beenproposed, such as
otal body weight (TBW) [20], and body mass index (BMI) [21,13].
t is noteworthy that a LMWHadapted regimen truly based on TBW
ould result in overdosing and increased bleeding risk, since LMWH
ave low lipophilic properties, and do not distribute into fat tissue,
ut remains in the vascular compartment. But given the paucity
f data and the heterogeneity of obesity phenotypes, it remains
nclear how LMWH regimen should be adapted to provide both
ufﬁcient efﬁcacy and safety. Accordingly, the prophylactic dose of
MWH is often increased according to a weight-scale based dosing
lgorithm,but capped in severelyobesepatients, resulting inaﬁxed
rbitrary dose for a heterogeneous group of patients.
In thisprospective real life study,weaimed tocompare the inﬂu-
nce of four body size descriptors (BSD) on peak anti-Xa levels at
teady-state in BS morbidly obese patients receiving a ﬁxed dou-
le dose of dalteparin (5000 IU subcutaneously, twice daily) for VTE
revention, in order to identify which one has the greatest impact,
nd could further be explored for an adjusted LMWH dosing algo-
ithm for achieving optimal VTE prevention in BS severely obese
atients.
. Methods
.1. Study design
This prospective monocentric study (NCT03218514) was per-
ormedbetween July 2014 andMarch 2017 at theDigestive Surgery
nit of North Hospital (Marseille, France). Patients between 18
nd 70 years old having a BMI≥40kg/m2, or ≥35kg/m2 with at
east one or more obesity-related co-morbidities including type
diabetes (T2DM), hypertension, obstructive sleep apnea (OSA),
on-alcoholic fatty liver disease, severe osteoarthritis, dyslipi-
emia, gastrointestinal disorders, or heart disease, scheduled for
leeve gastrectomy (SG) or gastric bypass procedure (GBP) and
greeing to participate in the study were prospectively enrolled.
xclusion criteria included anticoagulant administration within
8h preceding surgery, ongoing antiplatelet therapy, and preg-
ancy. LMWH were used according to the last French Society of
naesthesia and Intensive Care Guidelines on thromboprophylaxis
n BS [22]. Fixed-dose of dalteparin (5000 IU) were given subcuta-
eously twice daily for 14days. The ﬁrst dose was administered
ost-operatively, on the day of surgery (mean 6h). The present
tudy protocol conformed to the ethical guidelines of the 1964
eclaration of Helsinki, and was approved by the human research
ommittee of our institution. All patients gave an informed consent
o participate in the study.2.2. Data collection
Medical data including the type of BS performed, demographics,
BMI, obesity-related co-morbidities, prior history of venous throm-
boembolism, prior history of autoimmune disease, prior history of
malignancy, smoking status, total bed rest condition, and biolog-
ical data were retrieved from the electronic patient ﬁles. T2DM
was deﬁned according to the WHO criteria (fasting plasma glu-
cose≥7.0mmol/l (126mg/dl) or 2–h plasma glucose≥11.1mmol/l
(200mg/dl)), and/or being on antidiabetic drugs. Hypertensionwas
deﬁned as a blood pressure of above 140/90mmHg and/or being
on antihypertensive drugs. Dyslipidemia was deﬁned as the use of
statins and/or a raised total cholesterol level, LDL, or triglycerides
above the 95th percentile according to the deﬁnition proposed by
theAmericanHeart Association [23]. Obstructive sleep apnea (OSA)
was deﬁned as OSA proven with formal sleep study. Lean body
weight (LBW) was calculated according to the formula of Janma-
hasatian [24], ideal body weight (IBW) was calculated according to
the formula of Devine [25], and estimated globular ﬁltration rate
(eGFR) was computed according to the formula of Modiﬁcation of
Diet in Renal Disease (MDRD) [26].
2.3. Laboratory assessments
Blood samples were collected in 3.2% buffered trisodium citrate
tubes and twice centrifuged at 2500g for 15min at room temper-
ature to obtain platelet-poor plasma. Plasma was aliquoted and
stored at −80 ◦C until further analysis. Peak plasma levels of anti-
Xa activity were determined 4h after injection, at steady-state (at
least day 2 after thromboprophylaxis initiation) using the chro-
mogenic STA
®
-Rotachrom
®
Heparin assay (Stago, Asnières, France)
on a STA-R Evolution
®
analyzer (Stago, Asnières, France). Results
were expressed as peak anti-Xa levels (IU/ml).
2.4. Outcomes
Theprimaryoutcomeof the studywas theproportionofpatients
whose peak plasma anti-Xa levels were not in the prophylactic
ranges. The target range for prophylactic anti-Xa levelswas deﬁned
as 0.2–0.5 IU/ml [26]. Peak anti-Xa levels below 0.2 IU/ml were
deﬁned as subprophylactic, and above 0.5 IU/ml as supraprophy-
lactic. Subgroup analyses were conducted to determine whether
anti-Xa levels differed based on total bodyweight (TBW), LBW, IBW
or BMI stratum. TBW, LBW, IBW data were stratiﬁed into tertiles
andBMIdatawere stratiﬁed into3groups (group1, BMI <40kg/m2;
group2, 40≤BMI<50kg/m2; group3, BMI≥50kg/m2). A 3months
follow-upwas performed and symptomatic VTE aswell as bleeding
complications were recorded. Major bleeding complications were
deﬁned according to the International Society on Thrombosis and
Haemostasis criteria [27]. All other bleeding eventswere deﬁned as
minor. The secondary outcome was the occurrence of both symp-
tomatic VTE and major bleeding.
2.5. Statistical analysis
Statistical Analysis were performed using Graphpad Prism soft-
ware v7.0 for windows (Graphpad Software Inc., San Diego, USA).
Summary statistics were expressed as mean± standard deviation
of the mean [SD], or median and inter-quartile range [IQR] as
appropriate. The student t-test, the Mann-Whitney test and the
Kriskal-Wallis test were used for between comparisons of quan-
titative data, as appropriate. The chi-square test was used for
comparisons of categorical data. The spearman’s or the Pearson’s
test were used to measure the strength of association between two
variables, as appropriate. Multivariable analysis were performed
by analysis of covariance (ANCOVA) (Xlstat software; Addinsoft
®
,
Table 1
Baseline patient characteristics.
All (n =113) Sleevegastrectomy (n=89) Gastric by-pass (n =24) p
Age (years) 42(34–53) 42(34.5–53.5) 42(31–53) ns
Gender (women), n(%) 89(78.8) 65(73) 23(95.8) 0.0237
Total body weight (kg) 119(108–135.5) 117(108–135) 123(106–139) ns
Excess weight (kg) 49.1(41.7–66.7) 48.5(25.4–65.25) 55.3(24.2–70.73) ns
Lean body weight (kg) 56.4(51.9–64.9) 57.1(52.5–71) 55.2(51.6–61.8) ns
BMI (kg/m2) 43.3(40.6–48.7) 42.9(40.2–48.2) 45.6(41.9–50.1) ns
Comorbidities
Diabetes, n(%) 24(21.2) 20(22.5) 4(16.7) ns
Hypertension, n(%) 38(33.6) 32(36) 6(25) ns
Dyslipidemia, n(%) 28(24.8) 24(27) 4(16.7) ns
Current Smokers, n(%) 8(7) 6(6.7) 2(8.3) ns
OSA, n(%) 83(73.4) 67(75.3) 16(66.6) ns
Liver steatosis, n(%) 92(81.4) 73(82) 19(79.1) ns
Previous CAD, n(%) 0(0) 0(0) 0(0) ns
Previous VTE, n(%) 2(1.8) 2(2.3) 0(0) ns
Prior history of malignancy 7(6.2) 5(5.6) 2(8.3) ns
Prior history of autoimmune disease 4(3.5) 3(3.3) 1(4.1) ns
Bedridden patient 0(0) 0(0) 0(0) –
Combined oral contraceptives, n (%) 13(11.5) 12(13.4) 1(4.2) ns
eGFR(ml/min) 97.0±19.7 96.1±19.8 100.7±19.5 ns
Peak Anti Xa levels (IU/ml) 0.2±0.1 0.2±0.1 0.2±0.1 ns
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isease (MDRD).
LSTAT). Receiver operating characteristic (ROC) curves were
onstructed to assess the ability of the different BSD to predict sub-
rophylactic anti-Xa levels. Statistical signiﬁcancewas accepted for
< .05. The study had a power of 80% to detect a signiﬁcant corre-
ation (with r≥0.26, -risk 0.05, Student approximation) between
ach covariables and peak anti-Xa levels.
. Results
.1. Patient characteristics
From July 2014 through March 2017, 118 consecutive patients
ere enrolled in the study. Two patients did not meet all inclusion
riteria and 3 did not attend blood sampling. Finally, 113 patients
ere included in our prospective cohort. Baseline patient’s char-
cteristics are depicted in Table 1. Most of patients (n =89, 78.7%)
ad a SG, while 24 patients (21.3%) underwent a GBP. All surg-
ries were performed by laparoscopy. At inclusion, patients had
median age of 42 years (IQR, 34–53 years) and 89 (78.8%) were
omen. There was a higher proportion of women in the GBP group
Table 1). Median TBW was 119kg (IQR, 108–135.5 kg) and median
MI was 43.3 kg/m2 (IQR, 40.6–48.7).
.2. Peak anti-Xa levels based on TBW, LBW, IBW or BMI stratum
Peak plasma levels of anti-Xa activity were determined 4h after
njection, at steady-state (at least day 2 after thromboprophylaxis
nitiation). There were no missed doses or delays in dosing that
ould affect peak levels.Mean andmedian peak anti-Xa levelswere
.20±0.10 IU/mL and 0.19 IU/mL (IQR, 0.13–0.26 IU/mL), respec-
ively. Fifty-nine out of 113 patients (52%) did not achieve target
nti-Xa levels and 1 patient (0.08%) had a supraprophylactic level.
atients were further subdivided into increasing tertiles of TBW,
BW and IBW for subgroups analysis (Fig. 1). The percentage of
atients who did not achieve the target was signiﬁcantly higher in
he 3rd tertile of LBW (73% vs 28.9% and 57.9% in the 1st and 2nd
ertiles respectively, p = .0005) (Fig. 1). The type of surgery did not
nﬂuence anti-Xa levels.d deviation as appropriate; BMI, Body mass index; OSA, Obstructive sleep apnea;
r ﬁltration rate computed according to the formula of Modiﬁcation of Diet in Renal
3.3. Factors associated with anti-Xa levels
In univariate analysis, the following patient-related covari-
ates were signiﬁcantly associated with steady-state peak anti-Xa
levels: age (p= .014), gender (p <0.0001), TBW (p< .0001), LBW
(p< .0001), IBW (p< .001), BMI (p = .005) and eGFR (p= .016). The
strongest correlation was observed with LBW (r =−0.56, p < .0001)
(Fig. 2). Construction of ROC curves conﬁrmed that among the
four BSD, LBW had the highest sensitivity (73%) and speciﬁcity
(69%) to predict sub-prophylactic plasma anti-Xa levels (cut-off,
55.8 kg; area under the ROC curve, 0.76) (Fig. 3). In multivariate
analysis integrating age, gender and type of BS, only LBW (:-
0.47±0.08, p < .0001) and eGFR (:-0.19±0.08, p = .019) remained
independent predictors of peak anti-Xa levels (r2: 0.25; p < .0001).
Therewas no signiﬁcant correlation between these twoparameters
(r = 0.075, p = .438), which together were able to predict anti-Xa
levels according to the following equation: anti-Xa peak level
(IU/mL) =0.518− [0.00097× eGFR(ml/min)−0.0037× LBW(kg)].
3.4. Secondary outcomes
Neither VTE event nor major bleeding occurred during the 3
months follow-up period. One out of 113 patients (0.9%) having a
sub-prophylactic anti-Xa levels (0 IU/ml) presented a minor bleed-
ing.
4. Discussion
Considering the spectacular rise in BS procedures over the past
ten years worldwide [28], there is an urgent need to improve the
prevention of their postoperative complications. In the absence of
strong evidences or expert consensus statement, thromboprophy-
laxis remains a therapeutic challenge in severely obese patients
undergoingBS,whoare at higher risk of both thrombotic andbleed-
ing complications. In a recent nationwide cohort study including
more than 110 000 patients with a majority of SG, more than 0.5%
of patients experiencedVTE during the ﬁrst 90 post-operative days,
despite post hospital discharge chemoprophylaxis in 75% of cases,
suggesting that VTE remains a current concern in BS, particularly
in extreme body weights [29].
Fig. 1. Percentage of patients not achieving the target according to tertiles of total body weight (TBW) [A], tertiles of lean body weight (LBW) [B], tertiles of ideal body weight
(IBW) [C] or classes of body mass index (BMI) [D].
Fig. 2. Correlation between peak anti-Xa levels with total body weight (TBW) [A], lean body weight (LBW) [B], ideal body weight (IBW) [C] and body mass index (BMI) [D].
In the ﬁgure, 95% conﬁdence intervals are given for the regression line.
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redicting a subprophylactic peak antiXa level.
A growing body of evidence suggests that obese patients would
equire higher than standard ﬁxed LMWH dosing in order to
chieve adequate anticoagulation levels [16,30]. But considering
he LMWH pharmacokinetic properties, in severely obese patients,
truly weight-adapted dosing would result in overdosing. The use
f a body composition-scale based LMWH dosing algorithm repre-
ents thus an opportunity to achieve efﬁcient thromboprophylaxis
ith an acceptable safety. Therefore, in severely obese patients,
MWHare currently used at higher than standardﬁxeddosingwith
dose capping topreventoverdosingandbleeding complications. A
ecent meta-analysis of BS patients receiving prophylactic unfrac-
ionated heparin and LMWH showed that weight scale-stratiﬁed
mostly based on BMI) adjusted dosing tend to be associated with
ower VTE rates without excess in bleeding as compared with stan-
ard ﬁxed dosing [31]. However, whether LMWH dosing algorithm
hould be based on BMI or on another BSD in BS patients has never
een investigated before.
In the present study,wemeasured peak anti-Xa levels at steady-
tate in 113 BS severely obese patients receiving dalteparin 5000 IUweight (LBW) [B], ideal body weight (IBW) [C] and body mass index (BMI) [D] for
twice a day for VTE prevention. We found that only 48% of patients
achieved adequate anti-Xa levels. Our results are consistent with
other studies ﬁnding a low proportion of patients achieving ade-
quate anti-Xa levels, even when higher than standard ﬁxed dosing
of LMWH are used [11,16]. We thereafter compared the inﬂuence
of four BSD (TBW, LBW, IBW, and BMI) on steady-state anti-Xa lev-
els in order to determine which one could be further proposed for
an adjusted LMWH dosing algorithm for optimal VTE prevention
in severely obese patients. We found that LBW was strongly nega-
tively correlated with anti-Xa levels, and the ROC curves suggested
that LBW was the best predictor of subprophylactic anti-Xa lev-
els. A LBW above 55.8 kg indeed predicted subprophylactic anti-Xa
levels with a sensitivity of 72.9% and a speciﬁcity of 68.5%.
We also found a negative correlation observed between anti-
Xa levels and eGFR. LMWH elimination is mostly renal and this
negative correlation could be explained by the increased glomeru-
lar ﬁltration rate frequently observed in severe obese patients as
compared to normal-weight patients. At the opposite, the inﬂu-
ence of renal failure on LMWH accumulation has been extensively
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[ocumented. A creatinine clearance of 30mL/min or less has
een associated with elevated levels of anti-Xa (and also with an
ncreased risk for major bleeding) in patients treated with pro-
hylactic or therapeutic dose of LMWH. In a previous study of
2 consecutive patients hospitalized in geriatric care units receiv-
ng prophylactic doses of LMWH, there was a signiﬁcant negative
orrelation between anti-Xa levels and Cockcroft-Gault GFR [32].
Using multivariate analysis, LBW and eGFR remained signiﬁ-
antly associated with anti-Xa levels. LBW is a body size descriptor
hat can be measured with dual-energy X-ray absorptiometry
DXA), or estimated according to the formula of Janmmahasatian
t al. [24]. It represents the fat-free mass and a potential useful
redictor of the pharmacokinetic behavior of water soluble drugs
uch as LMWH [33], particularly in obese patients whose fat mass
xceeds fat-free mass. Lean body weight correlates with cardiac
utput and drug clearance and is arguably a used weight scalar to
alculate drug doses for obese patients [34].
To the best of our knowledge, two previous small sample size
harmacodynamics studies fromDiepstrassenet al. highlighted the
nterest of LBW in this setting [35,36]. The ﬁrst one (n=27) showed
hat LBW correlates with anti-Xa level, better than TBW or BMI
nd was the only BSD to correlate with the area under the anti-
a level-time curve from 0 to 24h (AUA0–24h) [35]. The second
ne (n=35) showed that LBW was the most predictive covariate
or central volume of distribution [36]. Interestingly, in our study
fter multivariate analysis, LBW and eGFR were signiﬁcantly asso-
iated with anti-Xa levels, the ﬁrst one probably reﬂecting LMWH
olume of distribution, and the second one LMWH clearance, but
BW had a greater effect on anti-Xa levels than eGFR as expressed
y the standardized coefﬁcients (:-0.47±0.08, p < .0001vs. :-
.19±0.08, p = .019).
A major limitation of our ﬁnding is that achieving anti-Xa
eak levels of 0.2–0.4 IU/mL speciﬁed by drug manufacturers has
een inconsistently associated with clinical outcomes and venous
hromboembolism incidence [37]. It is worth-noting that routinely
easuring anti-Xa concentrations in obese patients for the purpose
f monitoring the clinical effectiveness of LMWH is not warranted
et. Further understanding of prophylactic anti-Xa peak levels is
ence necessary before developing dosing algorithms.
In conclusion, LBW and eGFR are the main determinants of anti-
a level in BS obese patients receiving LMWH. This ﬁnding should
e considered when initiating thromboprophylaxis in this speciﬁc
opulation. Indeed, there are a lot of obesity phenotypes with dif-
erent adiposity and fat free mass distribution that warrant going
eyond BMI in LMWH dose adjustment. Considering that LMWH
roper dosing is critical in this setting, the efﬁcacy of a LBW-scale
ased dosing algorithm for optimal VTE prevention deserves fur-
her prospective randomized trials.
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